JP2015128433A5 - - Google Patents

Download PDF

Info

Publication number
JP2015128433A5
JP2015128433A5 JP2015030813A JP2015030813A JP2015128433A5 JP 2015128433 A5 JP2015128433 A5 JP 2015128433A5 JP 2015030813 A JP2015030813 A JP 2015030813A JP 2015030813 A JP2015030813 A JP 2015030813A JP 2015128433 A5 JP2015128433 A5 JP 2015128433A5
Authority
JP
Japan
Prior art keywords
seq
set forth
sequence set
nucleotide sequence
stretch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015030813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015128433A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015128433A publication Critical patent/JP2015128433A/ja
Publication of JP2015128433A5 publication Critical patent/JP2015128433A5/ja
Pending legal-status Critical Current

Links

JP2015030813A 2006-07-21 2015-02-19 プロテインキナーゼ３の発現を阻害するための手段 Pending JP2015128433A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06015262.6 2006-07-21
EP06015262 2006-07-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013034653A Division JP2013172714A (ja) 2006-07-21 2013-02-25 プロテインキナーゼ３の発現を阻害するための手段

Publications (2)

Publication Number Publication Date
JP2015128433A JP2015128433A (ja) 2015-07-16
JP2015128433A5 true JP2015128433A5 (enExample) 2015-08-27

Family

ID=38663298

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009519879A Pending JP2009544281A (ja) 2006-07-21 2007-07-20 プロテインキナーゼ３の発現を阻害するための手段
JP2013034653A Ceased JP2013172714A (ja) 2006-07-21 2013-02-25 プロテインキナーゼ３の発現を阻害するための手段
JP2015030813A Pending JP2015128433A (ja) 2006-07-21 2015-02-19 プロテインキナーゼ３の発現を阻害するための手段

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009519879A Pending JP2009544281A (ja) 2006-07-21 2007-07-20 プロテインキナーゼ３の発現を阻害するための手段
JP2013034653A Ceased JP2013172714A (ja) 2006-07-21 2013-02-25 プロテインキナーゼ３の発現を阻害するための手段

Country Status (12)

Country Link
US (1) US8232256B2 (enExample)
EP (2) EP2546337A1 (enExample)
JP (3) JP2009544281A (enExample)
KR (1) KR101670085B1 (enExample)
CN (3) CN101490253A (enExample)
AU (1) AU2007276388A1 (enExample)
BR (1) BRPI0714875A2 (enExample)
CA (1) CA2658550C (enExample)
HK (1) HK1208701A1 (enExample)
MX (1) MX2009000654A (enExample)
RU (1) RU2553561C2 (enExample)
WO (1) WO2008009477A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295611B1 (en) * 2000-06-20 2010-08-25 Dainippon Sumitomo Pharma Co., Ltd. Oligonucleotide-transferring preparations
ATE429930T1 (de) * 2001-06-20 2009-05-15 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
EP2992902A1 (en) 2004-12-27 2016-03-09 Silence Therapeutics GmbH Lipid complexes coated with peg and their uses
RU2553561C2 (ru) 2006-07-21 2015-06-20 Сайленс Терапьютикс Аг Средства ингибирования экспрессии протеинкиназы 3
WO2010110314A1 (ja) * 2009-03-27 2010-09-30 協和発酵キリン株式会社 核酸を含有する肺高血圧症治療剤
EP2382994A1 (en) * 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
US9133515B2 (en) 2012-05-16 2015-09-15 Silence Therapeutics Gmbh Use of VEGFR1 as a biomarker
WO2016083623A1 (en) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for the treatment of pre-eclampsia
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
RU2698199C1 (ru) * 2018-05-18 2019-08-23 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт общей патологии и патофизиологии" Средство для подавления экспрессии генов, связанных с накоплением холестерина макрофагами человека
CN120682233B (zh) * 2025-08-25 2025-12-12 浙江大学 Pkn3激酶抑制剂、药物组合物及pkn3激酶抑制剂的制备方法和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
KR940703846A (ko) 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
EP1251170A3 (en) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of NF-kappaB dependent animal diseases
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5777153A (en) 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
CA2227373A1 (en) 1995-07-21 1997-02-06 Promega Biosciences, Inc. Novel amide-based cationic lipids
AU743469C (en) 1996-08-30 2004-02-12 Rolf Bald Mirror-symmetrical selection and evolution of nucleic acids
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
CA2217550A1 (en) 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
US6358523B1 (en) 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
WO1998044909A1 (en) 1997-04-04 1998-10-15 Valentis Inc. Improved methods of delivery using cationic lipids and helper lipids
WO1998051285A2 (en) 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
JP2001510808A (ja) 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2315256A1 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
WO1999054459A2 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6150345A (en) 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
FR2788275B1 (fr) 1999-01-11 2002-06-14 Lipha ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7015040B2 (en) 1999-02-26 2006-03-21 Mirus Bio Corporation Intravascular delivery of nucleic acid
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
CA2383244A1 (en) 1999-05-28 2000-12-07 Sugen, Inc. Protein kinases
EP1064944A1 (en) 1999-06-25 2001-01-03 Schering Aktiengesellschaft Protein kinase N inhibitor comprising Fasudil
ES2235916T3 (es) 1999-07-15 2005-07-16 Inex Pharmaceuticals Corp. Preparacion de agentes terapeuticos de encapsulacion lipidica.
US6133032A (en) 1999-09-09 2000-10-17 Isis Pharmaceutical Inc. Antisense modulation of PI3 kinase p110 beta expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2003527856A (ja) 2000-03-17 2003-09-24 ベニテック オーストラリア リミテッド 遺伝子のサイレンシング
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
JP2004508012A (ja) 2000-04-20 2004-03-18 ザ　ユニバーシティ　オブ　ブリティッシュ　コロンビア エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法
JP2004511572A (ja) 2000-10-25 2004-04-15 ザ　ユニバーシティ　オブ　ブリティッシュ　コロンビア 標的化送達のための脂質製剤
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US6394713B1 (en) * 2001-03-05 2002-05-28 Phillip E. Yates, Sr. Drill guide apparatus
WO2003070910A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030135033A1 (en) 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
GB2397062B (en) 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
HUE039866T2 (hu) * 2002-08-05 2019-02-28 Silence Therapeutics Gmbh Az interferáló RNS molekulák további új formái
WO2004012680A2 (en) 2002-08-06 2004-02-12 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
EP1393742A1 (en) 2002-08-14 2004-03-03 atugen AG Use of protein kinase N beta
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
DE602004019546D1 (de) 2003-08-26 2009-04-02 Smithkline Beecham Corp Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
PT1771206T (pt) 2004-05-05 2018-05-16 Silence Therapeutics Gmbh Lípidos, complexos lipídicos e sua utilização
CA2587337A1 (en) 2004-11-19 2006-05-26 Novosom Ag Improvements in or relating to pharmaceutical compositions for local administration
EP2992902A1 (en) 2004-12-27 2016-03-09 Silence Therapeutics GmbH Lipid complexes coated with peg and their uses
WO2006074546A1 (en) 2005-01-13 2006-07-20 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
RU2553561C2 (ru) 2006-07-21 2015-06-20 Сайленс Терапьютикс Аг Средства ингибирования экспрессии протеинкиназы 3
RU2360967C1 (ru) * 2007-10-01 2009-07-10 Химический факультет Московского государственного университета имени М.В.Ломоносова Биокатализатор на основе иммобилизованных клеток бактерий для разложения метилфосфоновой кислоты и ее эфиров

Similar Documents

Publication Publication Date Title
JP2009544281A5 (enExample)
JP2013535212A5 (enExample)
JP2018513668A5 (enExample)
JP2017079759A5 (enExample)
JP2018512041A5 (enExample)
JP2017093448A5 (enExample)
JP2018512110A5 (enExample)
JP2015142558A5 (enExample)
JP2020500929A5 (enExample)
JP2015518721A5 (enExample)
JP2018518163A5 (enExample)
JP2017079776A5 (enExample)
JP2014527401A5 (enExample)
JP2013532952A5 (enExample)
JP2020509016A5 (enExample)
JP2017537626A5 (enExample)
JP2018530530A5 (enExample)
EP4527459A3 (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
JP2013511990A5 (enExample)
JP2016116520A5 (enExample)
HRP20191232T1 (hr) Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
JP2009514877A5 (enExample)
JP2010166916A5 (enExample)
JP2013226147A5 (enExample)